Thus, inhibiting oncogenic MAGE-TRIM28 ubiquitin ligase-mediated degradation of substrates such as FBP1 could be a therapeutic option for the treatment of advanced HCC. This evidence concerns the gene FBP1 and hepatocellular carcinoma.